Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting mTOR for cancer treatment.
Rubio-Viqueira B, Hidalgo M. Rubio-Viqueira B, et al. Among authors: hidalgo m. Curr Opin Investig Drugs. 2006 Jun;7(6):501-12. Curr Opin Investig Drugs. 2006. PMID: 16784020 Review.
Targeting mTOR for cancer treatment.
Rubio-Viqueira B, Hidalgo M. Rubio-Viqueira B, et al. Among authors: hidalgo m. Adv Exp Med Biol. 2006;587:309-27. doi: 10.1007/978-1-4020-5133-3_24. Adv Exp Med Biol. 2006. PMID: 17163174 Review.
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. Ma WW, et al. Among authors: hidalgo m. J Clin Oncol. 2009 Jun 1;27(16):2697-704. doi: 10.1200/JCO.2008.18.8383. Epub 2009 Apr 20. J Clin Oncol. 2009. PMID: 19380450 Free PMC article. Clinical Trial.
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Weekes CD, et al. Among authors: hidalgo m. Invest New Drugs. 2011 Oct;29(5):1057-65. doi: 10.1007/s10637-010-9413-7. Epub 2010 Mar 23. Invest New Drugs. 2011. PMID: 20306339 Free PMC article. Clinical Trial.
Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.
Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Arcaroli J, et al. Among authors: hidalgo m. Cancer Med. 2012 Oct;1(2):207-17. doi: 10.1002/cam4.27. Epub 2012 Aug 16. Cancer Med. 2012. PMID: 23342270 Free PMC article. Clinical Trial.
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M. Jimeno A, et al. Among authors: hidalgo m. Cancer Res. 2008 Apr 15;68(8):2841-9. doi: 10.1158/0008-5472.CAN-07-5200. Cancer Res. 2008. PMID: 18413752
Novel targets in solid tumors: MEK inhibitors.
Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG. Messersmith WA, et al. Among authors: hidalgo m. Clin Adv Hematol Oncol. 2006 Nov;4(11):831-6. Clin Adv Hematol Oncol. 2006. PMID: 17143253 Review.
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M. Jimeno A, et al. Among authors: hidalgo m. Mol Cancer Ther. 2006 Dec;5(12):3240-7. doi: 10.1158/1535-7163.MCT-06-0565. Mol Cancer Ther. 2006. PMID: 17172427 Clinical Trial.
1,228 results